前列腺癌生化复发PSMA PET/CT阴性后的优化影像策略
本AJR专家小组叙述性综述探讨前列腺癌生化复发患者PSMA PET/CT阴性后的影像策略与管理。文章回顾初次及重复PSMA PET/CT的诊断表现、预后因素、非PSMA示踪剂及其他影像方法的价值。基于现有证据形成共识声明,强调结合PSA动力学与肿瘤生物学指导影像选择。
要点
- 指南推荐不应因PSMA PET/CT阴性而停用补救性放疗
- 影像策略制定应结合PSA动力学与肿瘤生物学特征
- 重复PSMA PET/CT及非PSMA示踪剂在部分患者中可考虑应用
核心结论
- 前列腺癌生化复发患者PSMA PET/CT阴性后仍面临隐匿病灶与经验性治疗风险的平衡难题
- 影像策略共识强调依据PSA动力学和肿瘤生物学进行个体化选择,部分领域仍需更多数据支持
研究设计与样本
- 美国放射学杂志专家小组叙述性综述,系统回顾PSMA PET/CT阴性后影像策略相关证据
- 纳入初次及重复PSMA PET/CT检查、非PSMA放射性示踪剂及PET以外其他影像模态的研究
临床应用与阅片要点
- 对PSMA PET/CT阴性的生化复发患者,指南建议不应以此为由放弃补救性放疗
- 临床实践中常通过额外影像检查在补救治疗前尝试定位病灶
- 影像时机与方式选择可参考PSA动力学和肿瘤生物学相关预后因素
- 重复PSMA PET/CT及非PSMA示踪剂可能对部分阴性患者提供额外诊断价值
局限性
- 部分临床决策领域缺乏充分数据,需进一步研究以支持知情决策
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PSMA PET/CT has become widely incorporated into restaging algorithms for patients with biochemical recurrence (BCR) of prostate cancer, defined as a rising PSA level after attempted curative therapy. A substantial proportion of patients with BCR demonstrate no detectable disease on PSMA PET/CT. In these patients, management remains challenging as clinicians must balance risks of undertreatment of occult disease and potential morbidity of empiric salvage therapies with a potential missed therapeutic window from further diagnostic workup. Guidelines recommend not withholding salvage radiation therapy based on negative PSMA PET/CT results. In practice, additional imaging is frequently pursued to attempt to localize disease before salvage treatment. This AJR Expert Panel Narrative Review examines the available evidence addressing the ongoing uncertainty surrounding optimal imaging strategies and related management after a negative PSMA PET/CT examination in patients with BCR. We review performance characteristics of initial and repeat PSMA PET/CT examinations, explore prognostic factors that may guide imaging timing and selection, and evaluate the role of radiotracers other than PSMA and modalities other than PET. Based on the presented information, we provide consensus statements for imaging strategies emphasizing PSA kinetics and tumor biology while acknowledging areas where additional data are needed for informed clinical decision-making.
引用
- Choi, Almaguel, Franquet-Elia, et al. Optimal Imaging Strategies After Negative PSMA PET/CT Results in Patients With Prostate Cancer Biochemical Recurrence: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2026. PMID: 42455032. doi:10.2214/AJR.26.35081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。